

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO	0.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO. CONFIRMATION NO.	
10/608,054 06/27/2003		06/27/2003	Michael L.F. Chan	TRA-007 7895	
3897	7590	06/22/2006		EXAMINER	
SCHNEC	CK & S	SCHNECK	MILLER, BENA B		
P.O. BOX				ARTIBUT	DA DED MUMBED
SAN JOSE, CA 95109-0005				ART UNIT	PAPER NUMBER
				3725	

DATE MAILED: 06/22/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action							
Before	the Filing of an Appeal Brief	F					

Application No.	Applicant(s)	
10/608,054	CHAN, MICHAEL L.F.	
Examiner	Art Unit	
Bena Miller	3725	

	Bena Miller	3725	
The MAILING DATE of this communication appe	ars on the cover sheet with the c	orrespondence add	ress
THE REPLY FILED <u>30 May 2006</u> FAILS TO PLACE THIS APP	LICATION IN CONDITION FOR AL	LOWANCE.	
1. The reply was filed after a final rejection, but prior to or on this application, applicant must timely file one of the follow places the application in condition for allowance; (2) a No a Request for Continued Examination (RCE) in compliant time periods:	wing replies: (1) an amendment, aff tice of Appeal (with appeal fee) in (idavit, or other evider compliance with 37 C	nce, which FR 41.31; or (3)
a) A : The period for reply expires 3 months from the mailing date b) The period for reply expires on: (1) the mailing date of this A	•	in the final rejection, wh	ichever is later. In
no event, however, will the statutory period for reply expire lexaminer Note: If box 1 is checked, check either box (a) or	ater than SIX MONTHS from the mailing	g date of the final rejecti	on.
TWO MONTHS OF THE FINAL REJECTION. See MPEP 7 Extensions of time may be obtained under 37 CFR 1.136(a). The date	06.07(f).		·
Extensions of time may be obtained united 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of ex under 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office later may reduce any earned patent term adjustment. See 37 CFR 1.704(b) NOTICE OF APPEAL	tension and the corresponding amount shortened statutory period for reply orig r than three months after the mailing da	of the fee. The appropr inally set in the final Offi	iate extension fee ce action; or (2) as
 The Notice of Appeal was filed on A brief in comp 	pliance with 37 CEP 41 37 must be	filed within two mont	ne of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any exte a Notice of Appeal has been filed, any reply must be filed	nsion thereof (37 CFR 41.37(e)), to	avoid dismissal of th	e appeal. Since
<u>AMENDMENTS</u>	•		
 The proposed amendment(s) filed after a final rejection, They raise new issues that would require further co 	nsideration and/or search (see NO		ecause
 (b) They raise the issue of new matter (see NOTE belo (c) They are not deemed to place the application in beappeal; and/or 		ducing or simplifying	the issues for
(d) ☐ They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)).		ected claims.	
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment	(PTOL-324)
5. Applicant's reply has overcome the following rejection(s)			(1.02.02.1).
Newly proposed or amended claim(s) would be all non-allowable claim(s).		timely filed amendme	ent canceling the
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed:		ll be entered and an o	explanation of
Claim(s) allowed Claim(s) objected to: Claim(s) rejected:			
Claim(s) withdrawn from consideration:		• .	
AFFIDAVIT OR OTHER EVIDENCE			
 The affidavit or other evidence filed after a final action, bubecause applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 			
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome all rejections under appe	al and/or appellant fa	ils to provide a
10. ☐ The affidavit or other evidence is entered. An explanatio REQUEST FOR RECONSIDERATION/OTHER			
The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application in	n condition for allowa	nce because:
12. Note the attached Information Disclosure Statement(s).	(PTO/SB/08 or PTO-1449) Paper N	lo(s)	1
13. Other:	,	Benar	1,00.
		Bena Miller Primary Examiner	N CCC

Art Unit: 3725

Continuation of 11. does NOT place the application in condition for allowance because: in reference to Applicant's remarks that McIlhenney fails to teach an inner rectangular cross section with opposed top and bottom sections....said inner box having transparent wall through which said gift is visible", the Examiner disagrees. Figure 6 of McIlhenney teaches the claimed elements as mentioned above. As indicated in the previous Office Action, the Examiner considers the combination of 11 and 12 to meet the claimed inner box.

In reference to Applicant's Affidavit filed 11/28/05, the Applicant appear to further argue the concept of commercial success. In response the examiner points oùt that An applicant who is asseding commercial success to support its contention of nonobviousness bears the burden of proof of establishing a nexus between the claimed invention and evidence of commercial success. The Federal Circuit has acknowledged that applicant bears the burden of establishing nexus, stating: In the ex parte process of examining a patent application, however, the PTO lacks the means or resources to gather evidence which supports or refutes the applicant's assession that the sale constitute commercial success. C.f. Ex parte Remark! 15 USPQZd 1498, 1503 (Bd. Pat. App. & Int. Iggoltevidentiary routine of shlfting burdens in civil proceedings inappropriate in ex parte prosecution proceedings becâuse examiner has no available means for adducing evidence). Consequently, the PTO must rely upon the applicant to provide hard evidence of commercial success. In re Huang, 100 F.3d 135, 139-40, 40 USPQZd 1685, 1689 (Fed. Cir. 1996). See also In re GPAC, 57 F.3d 1573, 1580, 35 USPQZd 1 1 16, 1 121 (Fed. Cir. 1995)., In re Paulsen, 30 F.3d 1475, 1482, 31 USPQZd 1671, 1676 (Fed. Cir. 1994) (Evidence of commercial success of articles not covered by the claims subject to the 35 U.S.C. 103 rejection was not probative of nonobviousness). The term "nexus" designates a factually and legally sufficient connection between the evidence of commercial success and the claimed invention so that the evidence is of probative value in the determination of nonobviousness. Demaco Corp. v. F. Von Langsdoe Licensing Ltd., 851 F.2d 1387, 7 USPQZd 1222 (Fed. Cir. 1988)...

In considering evidence of commercial success, care should be taken to determine that the commercial success allegedê is directly derived from the invention claimed, in a marketplace where the consumer is free to choose on the basis of objective principles, and that such success is not the result of heavy promotion or advertising shift in advertising, consumption by purchasers normally tied to applicant or assignee, or other business events extraneous to the merits of the claimed invention, etc. In re Mageli, 470 F.2d 1380, 176 USPQ 305 (CCPA 1973) (conclusory statements or opinions that increased sales were due to the merits of the invention are entitled to little weightl; In re Noznick, 478 F.2d 1260, 178 USPQ 43 (CCPA 1973). In ex parte proceedings before the Patent and Trademark Office, an applicant must show that the claimed features were responsible for the commercial success of an article if the evidence of nonobviousness is to be accorded substantial weight. See In re Huang, 100 F.3d 135, 140, 40 USPQZd 1685, 1690 (Fed. Cir. 1996) (Inventor's opinion as to the purchaser's reason for buying the product is insufficient to demonstrate a nexus between the sales and the claimed invention.). Merely showing that there was commercial success of an adicle which embodied the invention is not sufficient. Ex parte Remark, 15 USPQZd 1498, 1502-02 (Bd. Pat. App. & Inter. 1990). Compare Demaco Corp. v. F. Von Langsdoe Licensing Ltd., 851 F.2d 1387, 7 USPQZd 1222 (Fed. Cir. 1988) (In civil litigation, a patentee does not have to prove that the commercial success is not due to other factors. "A requirement for proof of the negative of all imaginable contributing factors would be unfairly burdensome, and contrary to the ordinary rules of evidence.'). See also Pentec, Inc. v. Graphic Controls Corp., 776 F.2d 309, 227 USPQ 766 (Fed. Cir. 1985) (commercial success may have been attributable to extensive advertising and position as a market leader before the introduction of the patented productl; In re Fielder, 471 F.2d 690, 176 USPQ 300 (CCPA 1973) (success of invention could be due to recent changes in related technology or consumer demand', here success of claimed voting ballot could be due to the contemporary drive toward greater use of automated data processing techniques; EWP Corp. v. Reliance Universal, Inc., 755 F.2d 898, 225 USPQ 20 (Fed. Cir. 1985) (evidence of licensing is a secondary consideration which must be carefully appraised as to its evidentiary value because licensing programs may succeed for reasons unrelated to the unobviousness of the product or process, e.g., license is mutually beneficial or less expensive than defending infringement suits); Hybritech Inc. v. Monoclonal Antibodies, Inc., 802 F.2d 1367, 231 USPQ 81 (Fed. Cir. 1986) (Evidence of commercial success supported a conclusion of nonobviousness of claims to an immunometric "sandwich" assay with monoclonal antibodies. Patentee's essays became a market leader with 25% of the market within a few years. Evidence of advertising did not show absence of a nexus between commercial success aid the merits of the claimed invention because spending 25-35% of sales on marketing was not inordinate (mature companies spent 17-32% of sales in this market), and advertising served primarily to make industry aware of the product because this is not kind of merchandise that can be sold by advedising hyperbole.)

Although Applicant present an affidavit reflecting a positive public feedback, Applicant has not provided a nexus between their claimed product and its purported commercial success.